Director Health Economics and Outcomes Research
Daiichi Sankyo, Inc.
Feng Lin is Director of Health Economics and Outcomes Research at Daiichi Sankyo, Inc, leading HEOR and RWE strategies for multiple oncology products. Prior to joint Daiichi Sankyo, Feng was with Novartis for five years where she led economic modeling and real-world evidence generation across therapeutic areas. Before working in pharmaceutical industry, she was a Steven M. Teutsch Prevention Effectiveness Fellow at CDC.
Feng graduated from Purdue University with PH.D. in Biomedical Engineering. She also obtained a Master of Science in Computer Engineering from University of Michigan and a Bachelor of Science in Electrical Engineering from Tsinghua University in Beijing, China.
